Literature DB >> 17432925

Management of acute exacerbations of chronic obstructive pulmonary disease in the elderly : an appraisal of published evidence.

Ken M Kunisaki1, Kathryn L Rice, Dennis E Niewoehner.   

Abstract

Chronic obstructive pulmonary disease (COPD) is a debilitating disease with rising worldwide prevalence. Exacerbations of COPD cause significant morbidity and become more common with advancing age. Healthcare providers caring for elderly patients should therefore be familiar with effective treatments for exacerbations of COPD. An extensive body of literature has identified several effective drug therapies for exacerbations. These drugs include inhaled bronchodilators, systemic corticosteroids and antibacterials. The two main classes of inhaled bronchodilators are beta-adrenoceptor agonists and anticholinergics. These drugs optimise lung function during exacerbations, with neither class demonstrating clear superiority over the other. Systemic corticosteroids are effective when used either for inpatient or outpatient treatment of exacerbations. They hasten recovery from exacerbations and reduce relapse rates. Antibacterials decrease morbidity from exacerbations and may decrease mortality in the more severe exacerbations. Other effective therapies for the treatment of acute exacerbations of COPD include oxygen and non-invasive ventilation. Oxygen can be safely administered in acute exacerbations associated with hypoxaemia, with titration of oxygen delivery to a goal oxygen saturation of 90%. Non-invasive ventilation reduces the morbidity and mortality associated with acute exacerbations complicated by hypercapnic respiratory failure. Strategies to prevent COPD exacerbations include smoking cessation, long-acting inhaled beta-adrenoceptor agonists, inhaled long-acting anticholinergics, inhaled corticosteroids and vaccination. Mucolytic agents, pulmonary rehabilitation, and case management programmes may also reduce exacerbation risk, but the current evidence supporting these interventions is weaker.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17432925     DOI: 10.2165/00002512-200724040-00004

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  206 in total

Review 1.  The asthma-like pharmacology and toxicology of (S)-isomers of beta agonists.

Authors:  D Handley
Journal:  J Allergy Clin Immunol       Date:  1999-08       Impact factor: 10.793

2.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial.

Authors:  P S Burge; P M Calverley; P W Jones; S Spencer; J A Anderson; T K Maslen
Journal:  BMJ       Date:  2000-05-13

3.  Prognosis in chronic obstructive pulmonary disease: results from multicenter clinical trials.

Authors:  N R Anthonisen
Journal:  Am Rev Respir Dis       Date:  1989-09

4.  Is it really useful to repeat outpatient pulmonary rehabilitation programs in patients with chronic airway obstruction? A 2-year controlled study.

Authors:  K Foglio; L Bianchi; N Ambrosino
Journal:  Chest       Date:  2001-06       Impact factor: 9.410

5.  Smoking cessation guidelines for health professionals: an update. Health Education Authority.

Authors:  R West; A McNeill; M Raw
Journal:  Thorax       Date:  2000-12       Impact factor: 9.139

6.  [Effects of noninvasive positive pressure ventilation on gas exchange and patients' transformation in chronic obstructive pulmonary disease and respiratory failure].

Authors:  R Zhou; P Chen; H Luo; X D Xiang
Journal:  Hunan Yi Ke Da Xue Xue Bao       Date:  2001-06-28

7.  Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush.

Authors:  E Monsó; J Ruiz; A Rosell; J Manterola; J Fiz; J Morera; V Ausina
Journal:  Am J Respir Crit Care Med       Date:  1995-10       Impact factor: 21.405

8.  Acute angle-closure glaucoma as a complication of combined beta-agonist and ipratropium bromide therapy in the emergency department.

Authors:  S K Hall
Journal:  Ann Emerg Med       Date:  1994-04       Impact factor: 5.721

9.  Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease.

Authors:  G C Donaldson; T A R Seemungal; A Bhowmik; J A Wedzicha
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

10.  Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency.

Authors:  R K Albert; T R Martin; S W Lewis
Journal:  Ann Intern Med       Date:  1980-06       Impact factor: 25.391

View more
  4 in total

Review 1.  What defines abnormal lung function in older adults with chronic obstructive pulmonary disease?

Authors:  Nitin Y Bhatt; Karen L Wood
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

2.  Cardiopulmonary Rehabilitation in Elderly Patients with Heart Failure: A Prospective Cohort Study.

Authors:  Haitao Zhou; Aishu Dong; Xiaoqing Xu; Jianing Zhu; Bowen Shi
Journal:  J Healthc Eng       Date:  2022-04-01       Impact factor: 2.682

3.  Eight-step method to build the clinical content of an evidence-based care pathway: the case for COPD exacerbation.

Authors:  Cathy Lodewijckx; Marc Decramer; Walter Sermeus; Massimiliano Panella; Svin Deneckere; Kris Vanhaecht
Journal:  Trials       Date:  2012-11-29       Impact factor: 2.279

Review 4.  The precarious balance between 'supply' and 'demand' for health care: the increasing global demand for rehabilitation service for individuals living with chronic obstructive pulmonary disease.

Authors:  Michel D Landry; Elham Hamdan; Sabriya Al Mazeedi; Dina Brooks
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.